Want to see OCUL full AI Analyst Report?
OCUL Stock Chart & Stats
$8.50
-$0.11(-1.33%)
At close: 4:00 PM EDT
$8.50
-$0.11(-1.33%)
Day’s Range― - ―
52-Week Range$6.23 - $16.44
Previous CloseN/A
Volume1.17M
Average Volume (3M)2.70M
Market Cap
$1.79B
Enterprise Value$1.69K
Total Cash (Recent Filing)$598.64M
Total Debt (Recent Filing)$79.38M
Price to Earnings (P/E)―
Beta1.39
Next Earnings
Nov 09, 2026EPS Estimate
-0.36Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.42
Shares Outstanding218,960,360
10 Day Avg. Volume1,771,105
30 Day Avg. Volume2,702,734
Financial Highlights & Ratios
PEG Ratio-0.52
Price to Book (P/B)3.47
Price to Sales (P/S)43.86
P/FCF Ratio-10.48
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$25.78Price Target Upside203.27% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-1.51
Revenue Forecast (FY)$52.88M
Bulls Say, Bears Say
Bulls Say
Very High Gross MarginsSustained high-80s to low-90s gross margins indicate exceptional unit economics for the company’s ophthalmic products. This durable margin cushion supports reinvestment in R&D and commercialization, and reduces the scale required to approach operating leverage if SG&A growth is controlled.
Improved Balance-Sheet LeverageReduced leverage and a debt profile that is smaller relative to equity/assets lower near-term refinancing risk and give management more optionality to fund operations or partnerships. This provides structural flexibility while the company advances commercialization and pipeline programs.
Marketed Product & Proprietary PlatformHaving a commercial product (DEXTENZA) plus a proprietary sustained-release hydrogel platform delivers recurring product revenues and a technology moat. The combination supports longer-term revenue visibility, potential label expansions, and licensing opportunities across ophthalmic indications.
Bears Say
Heavy Ongoing Cash BurnPersistent negative operating and free cash flow means the business is not yet self-funding and will rely on external financing or partnerships. Over multiple quarters this raises execution and funding risk, constraining ability to scale commercialization or advance pipeline without dilution.
Worsening Operating Losses & Weak Revenue TrendDeclining revenue and increasing operating losses undermine progress toward profitability. Even with strong gross margins, continued top-line pressure and expanding losses suggest challenges in converting product economics into sustainable net income over the medium term.
Equity Dilution RiskA 10 million-share expansion of the incentive plan raises dilution risk for existing holders and signals potential reliance on equity to incentivize staff or fund operations. Repeated issuance could materially affect equity value and indicates funding may come via share-based compensation or capital raises.
Ocular Therapeutix News
OCUL FAQ
What was Ocular Therapeutix Inc’s price range in the past 12 months?
Ocular Therapeutix Inc lowest stock price was $6.23 and its highest was $16.44 in the past 12 months.
What is Ocular Therapeutix Inc’s market cap?
Ocular Therapeutix Inc’s market cap is $1.79B.
When is Ocular Therapeutix Inc’s upcoming earnings report date?
Ocular Therapeutix Inc’s upcoming earnings report date is Nov 09, 2026 which is in 92 days.
How were Ocular Therapeutix Inc’s earnings last quarter?
Ocular Therapeutix Inc released its earnings results on Aug 03, 2026. The company reported -$0.35 earnings per share for the quarter, beating the consensus estimate of -$0.395 by $0.045.
Is Ocular Therapeutix Inc overvalued?
According to Wall Street analysts Ocular Therapeutix Inc’s price is currently Undervalued.
Does Ocular Therapeutix Inc pay dividends?
Ocular Therapeutix Inc does not currently pay dividends.
What is Ocular Therapeutix Inc’s EPS estimate?
Ocular Therapeutix Inc’s EPS estimate is -0.36.
How many shares outstanding does Ocular Therapeutix Inc have?
Ocular Therapeutix Inc has 218,960,360 shares outstanding.
What happened to Ocular Therapeutix Inc’s price movement after its last earnings report?
Ocular Therapeutix Inc reported an EPS of -$0.35 in its last earnings report, beating expectations of -$0.395. Following the earnings report the stock price went up 2.815%.
Which hedge fund is a major shareholder of Ocular Therapeutix Inc?
Currently, no hedge funds are holding shares in OCUL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Ocular Therapeutix Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$25.78 (203.27% Upside)
$25.78 (203.27% Upside)
Blogger Sentiment
Bullish
OCUL Sentiment 63%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 31.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $360.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.3%
Last 30 Days ▼ 3.2%
Last 30 Days ▼ 3.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-28.64%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
48.74%
Trailing 12-Months
Company Description
Ocular Therapeutix Inc
Ocular Therapeutix, Inc. is a biopharmaceutical company specializing in the creation, advancement, and commercialization of ophthalmic treatments. Their innovative approach leverages a proprietary bioresorbable hydrogel technology to address a range of eye diseases and conditions. The company currently offers two key products: ReSure Sealant, an ophthalmic device designed to prevent fluid leakage from corneal incisions after cataract surgery, and DEXTENZA, a dexamethasone-based ophthalmic insert used to manage post-surgical inflammation and pain in the eye, as well as to treat allergic conjunctivitis. In addition to their commercial offerings, Ocular Therapeutix is actively developing several product candidates in various clinical stages, including: OTX-TKI, an axitinib intravitreal implant in Phase 1 clinical trials for wet age-related macular degeneration (AMD) and other retinal diseases. OTX-TIC, a travoprost intracameral implant, currently in Phase 2 studies for open-angle glaucoma and ocular hypertension. OTX-CSI, a cyclosporine intracanalicular insert that has successfully completed Phase 2 clinical trials for dry eye disease. OTX-DED, a dexamethasone intracanalicular insert undergoing Phase 2 evaluation for the temporary relief of dry eye symptoms. Strategic partnerships are also a significant part of Ocular Therapeutix's operations. This includes a collaboration with Regeneron Pharmaceuticals, Inc. focused on developing and commercializing products that combine Ocular Therapeutix's sustained-release hydrogel technology with Regeneron's large molecule VEGF-targeting compounds for retinal disease treatment. Another partnership with AffaMed Therapeutics Limited covers the development and commercialization of DEXTENZA and OTX-TIC. Additionally, a discovery-focused collaboration with Mosaic Biosciences aims to pinpoint novel targets and therapeutic agents for dry age-related macular degeneration (dAMD). Established in 2006, Ocular Therapeutix, Inc. maintains its headquarters in Bedford, Massachusetts.
OCUL Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in clinical trials and financial stability, with strong support from payers and successful trial execution. However, challenges such as market pricing pressure and potential enrollment difficulties in diabetic retinopathy trials were noted.View all OCUL earnings summariesOCUL Stock 12 Month Forecast
Average Price Target
$25.78
▲(203.27% Upside)
Technical Analysis
EyePoint Pharmaceuticals
―
RegenXBio
―
Tarsus Pharmaceuticals
―
Oculis Holding
―
Aura Biosciences Inc
―
Ownership Overview
2.72% Insiders
20.43% Mutual Funds
3.07% Other Institutional Investors
62.08% Public Companies and
Individual Investors